Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation with C-KIT mutation RUNX1::RUNX1T1 or CBFB::MYH11.

Trial Details

NCT ID
NCT06783790
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Avapritinib, azacitidine, Venetoclax
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Subjects met the criteria for recurrence after allogeneic transplantation: re-emergence of leukemia cells or bone marrow original cells in peripher…
  • Bone marrow molecular biology detected C-KIT D816 or C-KIT N822 mutations
  • Patients with CBFB::MYH11 gene or RUNX1::RUNX1T1 fusion gene detected.
  • Eastern Cancer Collaboration Group (ECOG) physical status score 0-2 points.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →